Abstract：Objective To explore the clinical value of combined detection of serum squamous cell carcinoma antigen （SCCA）, carcinoembryonic antigen （CEA） and cytokeratin 19 fragment （CYFRA21-1） in patients with cervical cancer.  Methods A total of 52 patients with cervical cancer admitted to our hospital from June 2019 to June 2021 were selected as group A. 52 healthy subjects in the same time period were randomly selected as group B. The levels of serum SCCA, CEA and CYFRA21-1 in the two groups were detectioned. Results The levels of SCCA, CEA and CYFRA21-1 in group A were all significantly higher than those in group B. The differences between the two groups were statistically significant（t＝38.268, 15.381, 34.455, all P＜0.05）; the differences between the level of SCCA, CEA and CYFRA21-1 in different stages of cervical cancer in group A were statistically significant （t＝25.856, 20.781, 31.773, all P＜0.05）; the positive rate of combined detection was higher than those of single serum SCCA, CEA and CYFRA21-1, and the differences between the above detections were statistically significant （χ2＝30.583, 24.471, 31.312, all P＜0.05）; the diagnostic sensitivity and accuracy of combined detection were significantly higher than those of single detection. The differences were statistically significant when comparing the above detections （χ2＝8.569, 6.325, both P＜0.05）; the differences between the specificity of the combined detection and the single detection were not statistically significant （χ2＝0.158, both P＞0.05）. Conclusion The levels of serum SCCA, CEA and CYFRA21-1 in patients with cervical cancer are significantly different from those in healthy people. Combined detection can improve the diagnostic accuracy and provide data support for treatment.